Keyword: Patrick Mahaffey
Clovis is facing several challenges that have biopharma experts speculating it will be snapped up by an asset-hungry Big Pharma player.
Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.
Clovis is one step away from a new use for its ovarian cancer drug Rubraca—and with FDA priority review, it could take that step early next year.
Clovis may be the middle child among next-gen ovarian cancer meds, but it’s hoping new data will open the therapy to a wave of new patients.